
I claim:

- 1. An immunological composition comprising two, three, or four distinct protein-polysaccharide conjugates, wherein each of the conjugates comprises a capsular polysaccharide from two or more serogroup of *N. meningitidis* conjugated to one or more a carrier protein(s).
- 2. The immunological composition of claim 1, wherein the capsular polysaccharides are selected from the group consisting of capsular polysaccharides from serogroups A, C, W-135 and Y of N. meningitidis
- 3. The immunological composition of claim 1, wherein the capsular polysaccharides are from serogroups A and C of *N. meningitidis*.
- 4. The immunological composition of claim 1, wherein the capsular polysaccharides are from serogroups A, C, W-135 and Y of *N. meningitidis*.
- 5. The immunological composition of claim 1, wherein the carrier protein in diphtheria toxoid.
- 6. The immunological composition of claim 1, further comprising an adjuvant.
- 7. The immunological composition of claim 5, wherein the adjuvant is aluminum hydroxide.
- 8. The immunological composition of claim 5, wherein the adjuyant is aluminum phosphate.
- 9. A method of inducing an immunological response to capsular polysaccharide of *N. meningitidis* comprising administering an immunologically effective amount of the immunological composition of claim 1 to a human or animal.
- 10. A multivalent meningococcal vaccine comprised of immunologically effective amounts of from two to four distinct protein-polysaccharide conjugates, wherein each of the conjugates contains a different capsular polysaccharide conjugated to a carrier protein, and wherein each capsular polysaccharide is selected from the group consisting of capsular polysaccharide from serogroups A, C, W-135 and Y.

L

· soldiel



- 12. The multivalent meningococcal vaccine of claim 9, wherein the capsular polysaccharides are prepared from serogroups A, C, W-135 and Y of N. meningitidis.
- 13. The multivalent meningococcal vaccine of claim 9, wherein the carrier protein is diphtheria toxoid.
- 14. The multivalent meningococcal vaccine of claim, 9, further comprising an adjuvant.
- 15. The multivalent meningococcal vaccine of claim 13, wherein the adjuvant is aluminum hydroxide.
- 16. the multivalent meningococcal vaccine of claim 13, wherein the adjuvant is aluminum phosphate.
- 17. A method of protecting a human or animal susceptible to infection from *N. meningitidis* comprising administering to the human or animal an immunologically effective amount of the vaccine of claim 9.